• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.腺病毒血清型 5 中和抗体在接种疫苗和自然感染后靶向六邻体和纤维。
J Virol. 2012 Jan;86(1):625-9. doi: 10.1128/JVI.06254-11. Epub 2011 Nov 9.
2
Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.腺病毒血清型 5 特异性中和抗体针对多个六邻体超变区。
J Virol. 2012 Jan;86(2):1267-72. doi: 10.1128/JVI.06165-11. Epub 2011 Nov 9.
3
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.针对5型腺病毒疫苗载体的中和抗体主要针对腺病毒六邻体蛋白。
J Immunol. 2005 Jun 1;174(11):7179-85. doi: 10.4049/jimmunol.174.11.7179.
4
Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions.人腺病毒 3 型(HAdV-3)和 HAdV-7 的血清型特异性中和抗体表位位于多个六邻体超变区。
J Virol. 2012 Aug;86(15):7964-75. doi: 10.1128/JVI.07076-11. Epub 2012 May 23.
5
Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo.操控腺病毒六邻体高变环可在体外和体内决定免疫中和作用以及凝血因子X依赖性细胞相互作用。
PLoS Pathog. 2015 Feb 6;11(2):e1004673. doi: 10.1371/journal.ppat.1004673. eCollection 2015 Feb.
6
Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon.构建并鉴定由 7 型腺病毒五邻体包装的 3 型人腺病毒。
Virus Res. 2011 Sep;160(1-2):214-20. doi: 10.1016/j.virusres.2011.06.017. Epub 2011 Jun 29.
7
Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.鉴定一种可提高 hexon 修饰的腺病毒载体产量的抑制突变。
J Virol. 2013 Sep;87(17):9661-71. doi: 10.1128/JVI.00462-13. Epub 2013 Jul 3.
8
Generation of neutralizing monoclonal antibodies against a conformational epitope of human adenovirus type 7 (HAdv-7) incorporated in capsid encoded in a HAdv-3-based vector.针对基于人腺病毒3型(HAdv-3)载体编码的衣壳中包含的人腺病毒7型(HAdv-7)构象表位产生中和性单克隆抗体。
PLoS One. 2014 Jul 23;9(7):e103058. doi: 10.1371/journal.pone.0103058. eCollection 2014.
9
Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector.对一种无钮、亲和体靶向的5型腺病毒载体的免疫反应性降低。
Gene Ther. 2007 Feb;14(4):376-81. doi: 10.1038/sj.gt.3302875. Epub 2006 Oct 12.
10
Interaction between hexon and L4-100K determines virus rescue and growth of hexon-chimeric recombinant Ad5 vectors.六邻体与L4-100K之间的相互作用决定了六邻体嵌合重组腺病毒5型载体的病毒拯救和生长情况。
Sci Rep. 2016 Mar 3;6:22464. doi: 10.1038/srep22464.

引用本文的文献

1
Systemic Delivery Strategies for Oncolytic Viruses: Advancing Targeted and Efficient Tumor Therapy.溶瘤病毒的全身递送策略:推进靶向高效肿瘤治疗
Int J Mol Sci. 2025 Jul 18;26(14):6900. doi: 10.3390/ijms26146900.
2
Research progress on human adenovirus sepsis.人类腺病毒败血症的研究进展
Front Pediatr. 2025 May 19;13:1552958. doi: 10.3389/fped.2025.1552958. eCollection 2025.
3
Chimeric Ad5/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency.嵌合型Ad5/35溶瘤腺病毒可克服预先存在的中和抗体并提高肿瘤靶向效率。
Cancer Gene Ther. 2025 Apr;32(4):418-436. doi: 10.1038/s41417-025-00884-x. Epub 2025 Mar 8.
4
An oncolytic HAdV-5 with reduced surface charge combines diminished toxicity and improved tumor targeting.一种表面电荷减少的溶瘤腺病毒5型兼具降低的毒性和改善的肿瘤靶向性。
Mol Ther Oncol. 2024 Nov 23;32(4):200909. doi: 10.1016/j.omton.2024.200909. eCollection 2024 Dec 19.
5
A humanized neutralizing antibody protects against human adenovirus type 7 infection in humanized desmoglein-2 and CD46 double-receptor transgenic mice.一种人源化中和抗体可预防人源化桥粒芯糖蛋白 2 和 CD46 双受体转基因小鼠感染人腺病毒 7 型。
Virol J. 2024 Nov 16;21(1):294. doi: 10.1186/s12985-024-02572-y.
6
Adenoviral fiber-knob based vaccination elicits efficient neutralizing antibodies and T cell responses against adenovirus infection.基于腺病毒纤维突的疫苗接种可引发针对腺病毒感染的高效中和抗体和 T 细胞应答。
Virol J. 2024 Oct 7;21(1):246. doi: 10.1186/s12985-024-02520-w.
7
Adenovirus infections: new insights for the clinical laboratory.腺病毒感染:临床实验室的新见解。
J Clin Microbiol. 2024 Sep 11;62(9):e0083622. doi: 10.1128/jcm.00836-22. Epub 2024 Aug 27.
8
The short fiber knobs of human adenovirus in species F elicit cross-neutralizing antibody responses.F 种人类腺病毒的短纤维结节可引发交叉中和抗体反应。
Heliyon. 2024 Aug 3;10(15):e35783. doi: 10.1016/j.heliyon.2024.e35783. eCollection 2024 Aug 15.
9
Coordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells.一名多发性骨髓瘤患者在接受靶向B细胞成熟抗原(BCMA)的嵌合抗原受体(CAR)T细胞治疗后发生系统性腺病毒感染时的协调抗病毒免疫反应
Blood Adv. 2024 Nov 26;8(22):5880-5884. doi: 10.1182/bloodadvances.2024012762.
10
Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.腺病毒载体系统:构建、治疗应用和宿主反应的全面概述。
J Microbiol. 2024 Jul;62(7):491-509. doi: 10.1007/s12275-024-00159-4. Epub 2024 Jul 22.

本文引用的文献

1
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.儿童和成人人群中腺病毒血清型 5、26、35 和 48 的国际血清流行病学研究。
Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25.
2
Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.自然感染或免疫诱导的 5 型腺病毒中和抗体的差异特异性和免疫原性。
J Virol. 2010 Jan;84(1):630-8. doi: 10.1128/JVI.00866-09.
3
Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.在人体中用一种Ad5 HIV-1候选疫苗免疫后的腺病毒特异性免疫。
Nat Med. 2009 Aug;15(8):873-5. doi: 10.1038/nm.1991. Epub 2009 Jul 20.
4
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.一种复制缺陷型5型腺病毒HIV-1 B亚型gag/pol/nef疫苗在健康成年人中的安全性和免疫原性。
Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993.
5
Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa.撒哈拉以南非洲地区人类体内的黑猩猩腺病毒抗体
Emerg Infect Dis. 2006 Oct;12(10):1596-9. doi: 10.3201/eid1210.060078.
6
Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies.DNA疫苗诱导的CD8+ T淋巴细胞表位免疫显性等级的调控
J Virol. 2006 Dec;80(24):11991-7. doi: 10.1128/JVI.01348-06. Epub 2006 Sep 27.
7
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.六邻体嵌合5型腺病毒载体可规避预先存在的抗载体免疫。
Nature. 2006 May 11;441(7090):239-43. doi: 10.1038/nature04721. Epub 2006 Apr 16.
8
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.针对5型腺病毒疫苗载体的中和抗体主要针对腺病毒六邻体蛋白。
J Immunol. 2005 Jun 1;174(11):7179-85. doi: 10.4049/jimmunol.174.11.7179.
9
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.在预先存在抗Ad5免疫力的情况下重组35型腺病毒疫苗的免疫原性。
J Immunol. 2004 May 15;172(10):6290-7. doi: 10.4049/jimmunol.172.10.6290.
10
Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.通过使用接受条件性复制腺病毒(ad dl1520)治疗肝肿瘤患者的血清来鉴定腺病毒五聚体基底中和表位。
J Virol. 2003 Oct;77(19):10366-75. doi: 10.1128/jvi.77.19.10366-10375.2003.

腺病毒血清型 5 中和抗体在接种疫苗和自然感染后靶向六邻体和纤维。

Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.

机构信息

Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

出版信息

J Virol. 2012 Jan;86(1):625-9. doi: 10.1128/JVI.06254-11. Epub 2011 Nov 9.

DOI:10.1128/JVI.06254-11
PMID:22072776
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3255879/
Abstract

The immunogenicity of adenovirus serotype 5 (Ad5) vectors has been shown to be suppressed by neutralizing antibodies (NAbs) directed primarily against the hexon hypervariable regions (HVRs). However, the role of NAbs directed against other capsid components, particularly the adenovirus fiber, remains unclear. Here we show that Ad5 NAbs target both hexon and fiber following vaccination and natural infection. Utilizing neutralization assays with capsid chimeric vectors, we observed that NAb responses to hexon appeared dominant and NAb responses against fiber were subdominant in sera from vaccinated mice, vaccinated humans, and naturally exposed humans. A novel chimeric Ad5 vector in which both the hexon HVRs and the fiber knob were exchanged nearly completely evaded Ad5-specific NAbs both in vitro and in vivo.

摘要

腺病毒血清型 5(Ad5)载体的免疫原性已被证明受到主要针对六邻体超变区(HVR)的中和抗体(NAb)的抑制。然而,针对其他衣壳成分(特别是腺病毒纤维)的 NAb 的作用仍不清楚。在这里,我们表明接种疫苗和自然感染后,Ad5 NAb 会靶向六邻体和纤维。利用衣壳嵌合载体的中和测定,我们观察到针对六邻体的 NAb 反应似乎占主导地位,而针对纤维的 NAb 反应在疫苗接种小鼠、疫苗接种人类和自然暴露人类的血清中则处于次要地位。一种新型嵌合 Ad5 载体,其中六邻体 HVR 和纤维扣均几乎完全交换,在体外和体内均能逃避 Ad5 特异性 NAb。